International Export Activities CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an emerging leader in global cannabis cultivation and export, is pleased to provide a corporate update outlining recent developments and strategic plans for 2026. During the fourth quarter, the Company continued its international export operations with an additional shipment of 250 kg (six batches) to Israel consistently increasing prices as quality increases. Three additional shipments ar ...

Core Insights - Novavax, Inc. has signed definitive agreements for site consolidation in Maryland, aiming to transform into a leaner and more agile organization, which is part of its corporate growth strategy [1][2] - The agreements are expected to generate $60 million in upfront payments and lead to future cost savings of $230 million over 11 years, primarily from lease expenses and facility operating costs [1][2] Financial Impact - The consolidation will result in $40 million from the assignment of the lease and sale of related assets, expected to close in January 2026 [2] - An additional $20 million is anticipated from the sale of adjacent property, expected to close in Q4 2025 [2] Strategic Focus - The company aims to enhance its focus on research and development (R&D) and partnerships, optimizing its existing capabilities while reducing costs [1][2] - Novavax's growth strategy includes expanding access to its technology platform through R&D innovation and new collaborations [3]

Financial Data and Key Metrics Changes - Novavax reported total revenue of $667 million for Q1 2025, a significant increase from $94 million in Q1 2024, driven by $622 million in product sales [28][29] - The company reduced current liabilities by over 60% compared to year-end 2024 and improved its cost structure by reducing combined R&D and SG&A costs by 24% year-over-year [29][36] - Net income for Q1 2025 was $519 million, or $2.93 per diluted share [35] Business Line Data and Key Metrics Changes - Product sales for Q1 2025 included $603 million from the closeout of the Canada and New Zealand APA agreements, allowing Novavax to retain cash previously received [29][33] - Supply sales of $14 million in Q1 2025 were primarily related to Matrix M adjuvant sales to licensed partners [34] Market Data and Key Metrics Changes - The partnership with Takeda has improved financial terms for Novavax in Japan, enhancing its position in the third-largest healthcare market globally [8][12] - Anticipated cash flows from licensed partners include $225 million in milestones from Sanofi and a $20 million upfront payment from Takeda [31][40] Company Strategy and Development Direction - The company is focusing on three strategic priorities: optimizing the partnership with Sanofi, leveraging its technology platform to forge additional partnerships, and advancing its tech platform and early-stage pipeline [9][43] - Novavax aims for non-GAAP profitability as early as 2027, with a disciplined investment strategy in high-potential value opportunities [7][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential approval of the BLA for the COVID vaccine and emphasized the importance of a non-mRNA protein-based vaccine option for U.S. consumers [10][11] - The company is actively seeking additional partnerships and collaborations to create multiple growth opportunities [12][13] Other Important Information - The company reiterated its full-year financial guidance for combined R&D and SG&A expenses of $475 million to $525 million, reflecting a 30% reduction compared to 2024 [30][38] - Novavax is working closely with the FDA on the parameters of the requested post-marketing commitment study related to its BLA [30][39] Q&A Session Summary Question: Nature of the post-marketing commitment FDA requested - Management has not publicly commented on the specifics of the study but is working diligently with the FDA to bring the process to a positive conclusion [46][47] Question: Target profile for KIC program and flu - The current study is designed to generate immunogenicity and safety data to inform the design of a phase three trial, not a pivotal trial [50][51] Question: Impact of the Utah Shield study on regulatory science - The Utah study is observational and not part of typical regulatory submissions; it informs consumer understanding rather than regulatory decisions [54][57] Question: Cash recognition from APA revenues - The $603 million recognized from Canada and New Zealand is non-cash, as the cash was received in prior years [71][72] Question: Safety profile of the combined vaccine - The study is designed to demonstrate immune response to both pathogens, with safety data to be supplemented from the immunogenicity data [79][80] Question: Confidence in receiving FDA approval of the BLA - Management sees a potential pathway forward for approval based on alignment on the post-marketing commitment [102][103]

Core Insights - Novavax, Inc. has appointed Charles Newton as an independent director to its board, bringing extensive experience in public markets and healthcare investment banking [1][2] - The company aims to leverage Mr. Newton's expertise to enhance its corporate growth strategy, focusing on strategic partnerships for its R&D assets and Matrix-M® adjuvant [2][3] Company Overview - Novavax is dedicated to addressing significant health challenges through its scientific expertise in vaccines and advanced technology platforms, including protein-based nanoparticles and the Matrix-M adjuvant [4] - The company's growth strategy emphasizes building diversified partnerships via out-licensing its technology and vaccine assets earlier in the development process, with a focus on infectious diseases and potential expansion into other areas [4]